DSM-Firmenich AG/€DSFIR
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About DSM-Firmenich AG
DSM-Firmenich AG, established in May 2023 through the merger of Dutch company DSM N.V. and Swiss company Firmenich SA, operates in the nutrition, health, and beauty industries. The company is organized into four segments: Perfumery & Beauty, offering fragrance solutions; Taste, Texture & Health, providing food and beverage ingredients; Health, Nutrition & Care, delivering dietary supplements and medical nutrition products; and Animal Nutrition & Health, supplying animal feed ingredients. Headquartered in Kaiseraugst, Switzerland, and Maastricht, Netherlands, DSM-Firmenich has operations in nearly 60 countries and employs approximately 30,000 people. The merger combines DSM's expertise in health and nutrition with Firmenich's capabilities in perfumery and taste, positioning the company to offer integrated solutions across its sectors. (,)
Ticker
€DSFIR
Sector
Primary listing
AEX
Employees
28,608
Headquarters
Kaiseraugst, Switzerland
Website
DSM-Firmenich AG Metrics
BasicAdvanced
€19B
27.90
€2.72
0.98
€2.50
1.40%
Price and volume
Market cap
€19B
Beta
0.98
52-week high
€112.64
52-week low
€71.30
Average daily volume
1.3K
Dividend rate
€2.50
Financial strength
Current ratio
2.695
Quick ratio
1.725
Long term debt to equity
24.079
Total debt to equity
25.242
Dividend payout ratio (TTM)
99.16%
Interest coverage (TTM)
5.99%
Profitability
EBITDA (TTM)
2,213
Gross margin (TTM)
35.02%
Net profit margin (TTM)
5.52%
Operating margin (TTM)
8.75%
Effective tax rate (TTM)
21.41%
Revenue per employee (TTM)
€450,000
Management effectiveness
Return on assets (TTM)
2.18%
Return on equity (TTM)
3.52%
Valuation
Price to earnings (TTM)
27.905
Price to revenue (TTM)
1.537
Price to book
0.94
Price to tangible book (TTM)
4.18
Price to free cash flow (TTM)
26.247
Free cash flow yield (TTM)
3.81%
Free cash flow per share (TTM)
2.888
Dividend yield (TTM)
3.30%
Forward dividend yield
1.40%
Growth
Revenue change (TTM)
4.46%
Earnings per share change (TTM)
-483.09%
3-year revenue growth (CAGR)
18.26%
10-year revenue growth (CAGR)
5.73%
3-year earnings per share growth (CAGR)
-25.00%
10-year earnings per share growth (CAGR)
57.35%
3-year dividend per share growth (CAGR)
-1.68%
10-year dividend per share growth (CAGR)
4.24%
Bulls say / Bears say
H1 2025 delivered 7% organic sales growth and a 29% increase in adjusted EBITDA to €1.26 billion, lifting the EBITDA margin to 19.4% and demonstrating strong volume and pricing power across the portfolio (GlobeNewswire).
Q1 2025 trading update reported 8% organic sales growth and a 40% rise in adjusted EBITDA (including an €85 million vitamin effect), driving the margin to 19.9% and confirming continued momentum in core segments (GlobeNewswire).
Completed the sale of its Feed Enzymes Alliance stake to Novonesis for €1.5 billion in June 2025, adding approximately €1.4 billion net proceeds to the balance sheet and strengthening liquidity for strategic investments and debt reduction (GlobeNewswire)
Perfumery & Beauty segment posted only 1% organic growth and a 22.0% adjusted EBITDA margin in H1 2025, reflecting weakness in Beauty & Care and indicating mixed demand in high-margin fragrances (Euronext).
Adjusted gross operating free cash flow in H1 2025 dropped to €215 million from €460 million in H1 2024, with sales-to-cash conversion at just 3.3% versus 7.3% a year earlier, highlighting pressure on cash generation (GlobeNewswire).
The full-year 2025 adjusted EBITDA outlook of approximately €2.4 billion depends on about €150 million of temporary vitamin price effects and roughly €100 million of synergy contributions, indicating underlying EBITDA growth may be modest once these one-off items fade (dsm-firmenich)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for DSM-Firmenich AG stock?
DSM-Firmenich AG (DSFIR) has a market cap of €19B as of October 25, 2025.
What is the P/E ratio for DSM-Firmenich AG stock?
The price to earnings (P/E) ratio for DSM-Firmenich AG (DSFIR) stock is 27.9 as of October 25, 2025.
Does DSM-Firmenich AG stock pay dividends?
Yes, the DSM-Firmenich AG (DSFIR) stock pays dividends to shareholders. As of October 25, 2025, the dividend rate is €2.5 and the yield is 1.4%. DSM-Firmenich AG has a payout ratio of 99.16% on a trailing twelve-month basis.
When is the next DSM-Firmenich AG dividend payment date?
The next DSM-Firmenich AG (DSFIR) dividend payment date is unconfirmed.
What is the beta indicator for DSM-Firmenich AG?
DSM-Firmenich AG (DSFIR) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.